CD79A and infection: Given that SARS-CoV-2 enters through the respiratory tract and that the respiratory tract is at least initially its primary site of replication, the impact of infection on mucosal IgA anti-SARS-CoV-2 S levels would likely be much greater than that of an intramuscular vaccine.